Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age
暂无分享,去创建一个
R. Adegbola | Yuxiao Tang | B. Plikaytis | G. Carlone | E. Marchetti | R. Borrow | B. Kampmann | M. Préziosi | M. Tapia | S. Sow | F. Haidara | F. Diallo | M. Doumbia | P. Kulkarni | G. Enwere | S. Viviani | A. Akinsola | O. Idoko | C. Elie | J. Chaumont | Lionel Martellet | F. Marc LaForce | Varsha Parulekar | H. Findlow
[1] R. Adegbola,et al. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] S. Hugonnet,et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study , 2013, The Lancet.
[3] N. Klein,et al. One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children , 2013, The Pediatric infectious disease journal.
[4] T. Vesikari,et al. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers , 2012, Human vaccines & immunotherapeutics.
[5] Ryan T Novak,et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. , 2012, Vaccine.
[6] C. Frasch,et al. Development of a group A meningococcal conjugate vaccine, MenAfriVacTM , 2012, Human vaccines & immunotherapeutics.
[7] D. Diop,et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. , 2011, The New England journal of medicine.
[8] N. Andrews,et al. Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine , 2009, Clinical and Vaccine Immunology.
[9] N. Ravenscroft,et al. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. , 2009, Vaccine.
[10] The immunological basis for immunization series Module , 2009 .
[11] G. Tzanakaki,et al. Conjugate vaccine-induced immunological priming is not protective against acute meningococcal C infection. , 2007, Vaccine.
[12] M. Préziosi,et al. The Meningitis Vaccine Project. , 2007, Vaccine.
[13] N. Andrews,et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. , 2006, The Journal of infectious diseases.
[14] E. Miller,et al. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned , 2006, Expert review of vaccines.
[15] D. Granoff,et al. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries , 2003, The Lancet.
[16] N. Andrews,et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. , 2002, The Journal of infectious diseases.
[17] N. Begg,et al. Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine , 2000, Epidemiology and Infection.
[18] G. Carlone,et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group , 1997, Clinical and diagnostic laboratory immunology.
[19] G. Carlone,et al. Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays , 1997 .
[20] B. Plikaytis,et al. Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992 , 1995, Clinical and diagnostic laboratory immunology.
[21] B. Plikaytis,et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay , 1992, Journal of clinical microbiology.